BOSTON, MA, USA & CAMBRIDGE, UK I June 19, 2025 I Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction ...

In-vitro lab results confirmed that the Company’s cell targeting nanoparticles successfully entered cancer cells and avoided non-cancerous cells ...

COPENHAGEN, Denmark I June 18, 2025 I Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...

Combination of World Leading Epitranscriptomics and AI-Driven Automation Aims to Accelerate Development of Cancer Therapies That Halt Metastasis ...

CAMBRIDGE, MA, USA I June 18, 2025 I Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The ...

HONG KONG, China I June 19, 2025 I Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to ...

SKY-0515 is an oral small molecule designed to reduce the production of both huntingtin (HTT) and PMS1 proteins—two key drivers of HD pathology ...

PHILADELPHIA, PA, USA I June 17, 2025 I Integral Molecular, the industry leader in discovering antibodies against membrane proteins, is pleased to announce ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease ...

Interim data on the cancer treatment shows robust potential for balancing efficacy and safety. TAIPEI, Taiwan and SHANGHAI, China and SAN FRANCISCO, CA, USA I June 17, 2025 I Foll ...

SANTIAGO DE COMPOSTELA, Spain & SHANGHAI, China I June 17, 2025 I SunRock Biopharma and Escugen have joined forces in a strategic partnership to ...

Clinical validation of stem cell reactivation approach positions Pelage as leader in regenerative medicine and aging ...